Anavex Life Sciences (AVXL) Notes Payables (2011 - 2015)
Anavex Life Sciences recorded quarterly Notes Payables of $92516.0 in Q2 2015, up 2.33% quarter-over-quarter from $90412.0 in Q1 2015, and down 53.93% year-over-year from $200835.0 in Q2 2014.
Anavex Life Sciences' Notes Payables history runs 5 years deep, the most recent figure standing at $92516.0 for Q2 2015.
- In Q2 2015, Notes Payables fell 53.93% year-over-year to $92516.0; the TTM figure through Jun 2015 stood at $92516.0 (down 53.93% YoY), while the FY2014 annual figure was $192065.0, down 8.91% from the prior year.
- Notes Payables came in at $92516.0 for Q2 2015 at Anavex Life Sciences, up from $90412.0 in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $1.2 million in Q1 2012 to a low of $49000.0 in Q2 2012.
- A 5-year average of $387573.7 and a median of $200835.0 in 2014 frame the typical range for Notes Payables.
- Across the five-year window, Notes Payables soared 1446.12% in 2013 and plunged 74.55% in 2014, its largest moves.
- Anavex Life Sciences' Notes Payables stood at $867919.0 in 2011, then sank by 30.98% to $599000.0 in 2012, then plunged by 66.55% to $200364.0 in 2013, then plunged by 50.93% to $98312.0 in 2014, then decreased by 5.9% to $92516.0 in 2015.
- According to Business Quant data, Notes Payables over the past three periods registered $92516.0, $90412.0, and $98312.0 for Q2 2015, Q1 2015, and Q4 2014 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2015 | 92,516.00 |
| Mar 31, 2015 | 90,412.00 |
| Dec 31, 2014 | 98,312.00 |
| Sep 30, 2014 | 192,065.00 |
| Jun 30, 2014 | 200,835.00 |
| Mar 31, 2014 | 193,720.00 |
| Dec 31, 2013 | 200,364.00 |
| Sep 30, 2013 | 210,863.00 |
| Jun 30, 2013 | 757,600.00 |
| Mar 31, 2013 | 761,292.00 |
| Dec 31, 2012 | 599,000.00 |
| Sep 30, 2012 | 299,000.00 |
| Jun 30, 2012 | 49,000.00 |
| Mar 31, 2012 | 1.20 Mn |
| Sep 30, 2011 | 867,919.00 |